FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2106084995> ?p ?o ?g. }

• W2106084995 endingPage "1761" @default.
• W2106084995 startingPage "1752" @default.
• W2106084995 abstract "Background Treatment with antithrombin (AT)-III is indicated for patients with sepsis or hereditary AT deficiency. Objective The purpose of this study was to compare the pharmacokinetic and pharmacodynamic characteristics of 2 AT-III formulations in healthy Korean volunteers to satisfy the regulatory requirements for bioequivalence for marketing purposes. Methods A single-center, single-dose, open-label, randomized, 2-period, 2-sequence crossover study was conducted in healthy Korean volunteers. Blood samples for the drug analysis were collected for up to 216 hours after drug administration. Participants received either the test or reference formulation of AT-III 100 U/kg IV for 20 minutes in the first period and the alternative formulation in the second period. Both the AT-III activity and antigen (Ag) were measured for the analysis of pharmacokinetic properties, and the prothrombin time and the activated partial thromboplastin time were assessed for the analysis of pharmacodynamic properties. Because AT-III is an endogenous compound, the analysis used data corrected from baseline values. The tolerability of the 2 formulations was also assessed based on physical examinations including vital sign measurements, laboratory tests, and 12-lead ECG. Results Of the 20 subjects enrolled (mean [SD] age, height, and weight, 25.3 [2.3] years, 175.3 [4.5] cm, and 67.4 [6.3] kg, respectively), 19 completed both treatment periods; 1 subject withdrew consent for personal reasons. The observed mean (SD) Cmax, AUClast, and AUC0–∞ of AT-III activity were, respectively, 279.24% (35.92), 14,364.10 (2325.25) %·h, and 17,526.38 (3150.81) %·h with the test formulation and 249.75% (31.96), 12,962.95 (1897.52) %·h, and 15,957.67 (3189.21) %·h with the reference formulation. The observed mean (SD) Cmax, AUClast, and AUC0–∞ of AT-III Ag were 62.58 (5.66) mg/dL, 3051.94 (401.87) mg/dL·h, and 3639.80 (726.01) mg/dL·h, respectively, with the test formulation and 58.63 (5.27) mg/dL, 2805.08 (272.38) mg/dL·h, and 3340.00 (428.46) mg/dL·h with the reference formulation. The geometric mean ratios (90% CI) of the log-transformed data for AT-III activity between the 2 formulations were 1.11494 (1.08994–1.14053) for Cmax, 1.11305 (1.05435–1.17503) for AUClast, and 1.11527 (1.03754–1.19889) for AUC0–∞; corresponding values for AT-III Ag were 1.08802 (1.06258–1.11405), 1.10905 (1.05804–1.16242), and 1.11460 (1.02058–1.21726). During the study period, 8 adverse events were reported, and all were transient, mild, and resolved completely during the treatment period. Conclusion The results of the present study showed that these 2 AT-III formulations met the regulatory criteria for pharmacokinetic bioequivalence with respect to AT-III activity and Ag in these healthy Korean subjects. ClinicalTrials.gov identifier: NCT00846274." @default.
• W2106084995 created "2016-06-24" @default.
• W2106084995 creator A5015481616 @default.
• W2106084995 creator A5022753869 @default.
• W2106084995 creator A5047444330 @default.
• W2106084995 creator A5050866517 @default.
• W2106084995 date "2013-11-01" @default.
• W2106084995 modified "2023-09-26" @default.
• W2106084995 title "Bioequivalence of Two Intravenous Formulations of Antithrombin III: A Two-Way Crossover Study in Healthy Korean Subjects" @default.
• W2106084995 cites W1555619669 @default.
• W2106084995 cites W162541770 @default.
• W2106084995 cites W1971980948 @default.
• W2106084995 cites W1978222180 @default.
• W2106084995 cites W2005888993 @default.
• W2106084995 cites W2022132254 @default.
• W2106084995 cites W2024169623 @default.
• W2106084995 cites W2037598189 @default.
• W2106084995 cites W2037698344 @default.
• W2106084995 cites W2060603007 @default.
• W2106084995 cites W2081010801 @default.
• W2106084995 cites W2081380404 @default.
• W2106084995 cites W2089136912 @default.
• W2106084995 cites W2091462103 @default.
• W2106084995 cites W2095067305 @default.
• W2106084995 cites W2095823426 @default.
• W2106084995 cites W2124401426 @default.
• W2106084995 cites W2133206482 @default.
• W2106084995 cites W2139651041 @default.
• W2106084995 cites W2320208683 @default.
• W2106084995 cites W2401367915 @default.
• W2106084995 cites W2404592538 @default.
• W2106084995 cites W2470152248 @default.
• W2106084995 cites W3021424465 @default.
• W2106084995 doi "https://doi.org/10.1016/j.clinthera.2013.08.018" @default.
• W2106084995 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24094463" @default.
• W2106084995 hasPublicationYear "2013" @default.
• W2106084995 type Work @default.
• W2106084995 sameAs 2106084995 @default.
• W2106084995 citedByCount "1" @default.
• W2106084995 countsByYear W21060849952016 @default.
• W2106084995 crossrefType "journal-article" @default.
• W2106084995 hasAuthorship W2106084995A5015481616 @default.
• W2106084995 hasAuthorship W2106084995A5022753869 @default.
• W2106084995 hasAuthorship W2106084995A5047444330 @default.
• W2106084995 hasAuthorship W2106084995A5050866517 @default.
• W2106084995 hasConcept C111113717 @default.
• W2106084995 hasConcept C112705442 @default.
• W2106084995 hasConcept C126322002 @default.
• W2106084995 hasConcept C142724271 @default.
• W2106084995 hasConcept C197934379 @default.
• W2106084995 hasConcept C204787440 @default.
• W2106084995 hasConcept C22979827 @default.
• W2106084995 hasConcept C27081682 @default.
• W2106084995 hasConcept C2778261982 @default.
• W2106084995 hasConcept C2778375690 @default.
• W2106084995 hasConcept C2778382381 @default.
• W2106084995 hasConcept C2780434524 @default.
• W2106084995 hasConcept C42404028 @default.
• W2106084995 hasConcept C71924100 @default.
• W2106084995 hasConcept C87813604 @default.
• W2106084995 hasConcept C98274493 @default.
• W2106084995 hasConceptScore W2106084995C111113717 @default.
• W2106084995 hasConceptScore W2106084995C112705442 @default.
• W2106084995 hasConceptScore W2106084995C126322002 @default.
• W2106084995 hasConceptScore W2106084995C142724271 @default.
• W2106084995 hasConceptScore W2106084995C197934379 @default.
• W2106084995 hasConceptScore W2106084995C204787440 @default.
• W2106084995 hasConceptScore W2106084995C22979827 @default.
• W2106084995 hasConceptScore W2106084995C27081682 @default.
• W2106084995 hasConceptScore W2106084995C2778261982 @default.
• W2106084995 hasConceptScore W2106084995C2778375690 @default.
• W2106084995 hasConceptScore W2106084995C2778382381 @default.
• W2106084995 hasConceptScore W2106084995C2780434524 @default.
• W2106084995 hasConceptScore W2106084995C42404028 @default.
• W2106084995 hasConceptScore W2106084995C71924100 @default.
• W2106084995 hasConceptScore W2106084995C87813604 @default.
• W2106084995 hasConceptScore W2106084995C98274493 @default.
• W2106084995 hasIssue "11" @default.
• W2106084995 hasLocation W21060849951 @default.
• W2106084995 hasLocation W21060849952 @default.
• W2106084995 hasOpenAccess W2106084995 @default.
• W2106084995 hasPrimaryLocation W21060849951 @default.
• W2106084995 hasRelatedWork W1541103017 @default.
• W2106084995 hasRelatedWork W2061170043 @default.
• W2106084995 hasRelatedWork W2073621733 @default.
• W2106084995 hasRelatedWork W2104641112 @default.
• W2106084995 hasRelatedWork W2106084995 @default.
• W2106084995 hasRelatedWork W2164900475 @default.
• W2106084995 hasRelatedWork W2333124717 @default.
• W2106084995 hasRelatedWork W2611950068 @default.
• W2106084995 hasRelatedWork W2626992247 @default.
• W2106084995 hasRelatedWork W2777540367 @default.
• W2106084995 hasVolume "35" @default.
• W2106084995 isParatext "false" @default.
• W2106084995 isRetracted "false" @default.
• W2106084995 magId "2106084995" @default.
• W2106084995 workType "article" @default.